UroGen Pharma Ltd. (NASDAQ: URGN) is a Healthcare company (Biotechnology) with a market capitalization of $1.5B. The Maz Rating grades it against the other companies in its sector.
UroGen Pharma Ltd.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.87, UroGen Pharma Ltd. trades at 5.7x sales. Over the last twelve months it generated about $256M of revenue and a net loss of $66M. It runs a gross margin of 91.4%, an operating margin of -12.4% and a net margin of -26.3%. It shows return on equity of 54.0%, return on invested capital of -15.5% and a free cash flow yield of -9.0%. On the balance sheet: a debt-to-equity ratio of -1.57 and a current ratio of 3.40. Over the past 52 weeks the share price ranged from $16.50 to $50.81, with a beta of 1.64.
UroGen Pharma Ltd. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 12 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, UroGen Pharma Ltd. (URGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.71% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.85% / 30% · Interest income / Revenue 0.77% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 9.71% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.64% / 33% · Receivables / Mkt Cap (36m) 6.01% / 49% · Interest income / Revenue 0.77% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 9.71% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.64% / 33.33% · Receivables / Mkt Cap (24m) 6.01% / 33.33% · Interest income / Revenue 0.77% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 70.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 47.1% / 33.33% · Receivables / Avg Assets (4Q) 30.1% / 33.33% · Interest income / Revenue 0.77% / 5% | Fail |
| FTSE | Debt / Total Assets 69.6% / 33.33% · (Cash+ST Inv) / Total Assets 33.3% / 33.33% · (Cash+Recv) / Total Assets 76.4% / 33.33% · Interest income / Revenue 0.77% / 5% | Fail |
It depends on the standard you follow. As of September 2026, UroGen Pharma Ltd. (URGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. UroGen Pharma Ltd. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.77% of each dividend: UroGen Pharma Ltd.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.